HIV Treatment Bulletin - Vol. 6, No. 1, December 2004 / January 2005
Graham McKerrow, HIV i-Base

A Spanish study of 61 HIV-positive men on ARV therapy found endothelial dysfunction (ED) in 18%, a similar proportion to naïve patients. Its presence was independent of fat redistribution abnormalities, plasma adipokines, lipoproteins, immune status or use of PIs or NNRTIs.

Low adiponectin (AD) plasma levels are observed in patients on treatment with fat redistribution abnormalities (FRA) and low levels of adiponectin have been associated with impaired vasoreactivity in the general population. Previous studies found a significant relationship between use of PIs and endothelial dysfunction.

Estrada and colleagues in Madrid analysed the relationships between plasma AD, FRA, and endothelial function as measured by high-resolution ultrasound. Of the 61 ART-experienced people studied, 44.2% presented with FRA, most of them with lipoatrophy.

Mean flow-mediated vasodilation (FMD) of patients on ARV treatment was 11.6% (IC 95%, 8.3-14.9) similar to control group, 11.7% (IC 95%, 7.4-16), p=NS. The proportion of patients who presented ED was similar between treated 11/61 (18%) and naïve groups 6/17 (35,3%) p=ns. There was a significant correlation between FMD and vasodilator response to nitrates (r=0,48, p=0,001). Plasma adiponectin, leptin, lipoproteins, insulin, CD4 lymphocyte count, HIV-1 viral load, did not correlate with FMD. Presence of fat distribution changes did not influence FMD values. Patients on PI or NNRTI showed similar FMD values. In multivariate linear regression analyses, only basal artery diameter significantly contributed to FMD.

Ref: Estrada V, Zamorano JL, Sainz T et al. Endothelial dysfunction, adiponectin plasma levels and lipodystrophy in patients on antiretroviral therapy. 6th Lipodystrophy Workshop (6th IWADRLH), Washington. Antiviral Therapy 2004; 9:L66 Abstract 117.

041210
IB050601-11

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.